Summaries for Patients |

Outcomes of Chronic Infection with Hepatitis B Virus FREE

[+] Article, Author, and Disclosure Information

The summary below is from the full report titled “Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus.” It is in the 6 November 2001 issue of Annals of Internal Medicine (volume 135, pages 759-768). The authors are BJ McMahon, P Holck, L Bulkow, and M Snowball.

Ann Intern Med. 2001;135(9):S50. doi:10.7326/0003-4819-135-9-200111060-00002
Text Size: A A A

What is the problem and what is known about it so far?

Hepatitis B is an inflammation of the liver that is caused by a virus. The virus spreads through contact with infected body fluids. Most people who get hepatitis B recover within a few months, but some develop chronic infection. Chronic infection increases one's risk for liver failure and liver cancer. Persons with chronic infection often have viral-related protein substances in their blood (called hepatitis B surface antigens and e antigens) for many years. When e antigen is present, it usually means that the person has very active liver disease and a lot of virus present. Eventually, the body's natural defense system clears e antigen in most persons and surface antigen in a small percentage of persons. Exactly how often the body clears hepatitis B antigens on its own and how many people with chronic infection develop liver failure and liver cancer are not completely understood.

Why did the researchers do this particular study?

To describe the time course of clearance of viral antigens and outcomes in people with chronic hepatitis B.

Who was studied?

1536 Alaska Natives with chronic hepatitis B. The people studied ranged in age from 1 to 87 years; the average age was 20 years.

How was the study done?

Participants were identified by using a registry that had records from multiple statewide surveys done in the 1970s and 1980s. All participants had documented chronic infection, defined as two positive blood tests for hepatitis B surface antigen on two separate occasions at least 12 months apart. All had repeated blood sampling at 6-month intervals as part of a program to try to detect liver cancer at a treatable stage. The duration of follow-up ranged from 1 to 33 years. Computerized medical records and death certificates were reviewed to assess liver failure and liver cancer outcomes. The researchers used special analysis methods to examine the time course of clearance of antigens.

What did the researchers find?

Seven percent of the participants cleared hepatitis B surface antigen during follow-up. About 40% tested positive for hepatitis e antigen at baseline. The probability of clearing e antigen was about 40% within 5 years and 70% within 10 years. About 15% of people who were negative for e antigen became positive again at some time during follow-up. Only 9 people received antiviral therapy (interferon or lamivudine). Eight people died of liver failure, and 36 got liver cancer. People who changed from being negative for e antigen to being positive had higher risk for liver cancer than did those who remained negative for e antigen.

What were the limitations of the study?

The study included only Alaska Natives. Other ethnic groups might have different time courses and outcomes. The study does not address whether antiviral therapy can change the course of chronic hepatitis B.

What are the implications of the study?

Most people (about 70%) with chronic hepatitis B will clear hepatitis e antigen within 10 years without antiviral therapy. A few (about 15%) will revert from being negative for e antigen to being positive. Persons who change from being negative to being positive have a higher risk for liver cancer. These people and people who do not clear e antigen might be good candidates for antiviral therapy.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.